Price
CHART BY
Frequently asked questions
What is MaxCyte's market capitalization?
The market capitalization of MaxCyte is $119.72M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for MaxCyte?
MaxCyte's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.334. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for MaxCyte's stock?
Currently, 6 analysts cover MaxCyte's stock, with a consensus target price of $4.10. Analyst ratings provide insights into the stock's expected performance.
What is MaxCyte's revenue over the trailing twelve months?
Over the trailing twelve months, MaxCyte reported a revenue of $31.05M.
What is the EBITDA for MaxCyte?
MaxCyte's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$27.25M. EBITDA measures the company's overall financial performance.
What is the free cash flow of MaxCyte?
MaxCyte has a free cash flow of -$23.64M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does MaxCyte have, and what sector and industry does it belong to?
MaxCyte employs approximately 91 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of MaxCyte's shares?
The free float of MaxCyte is 94.76M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $119.72M
- EPS (TTM)
- -$0.334
- Free Float
- 94.76M
- Revenue (TTM)
- $31.05M
- EBITDA (TTM)
- -$27.25M
- Free Cashflow (TTM)
- -$23.64M
Pricing
- 1D span
- $1.163$1.218
- 52W span
- $0.646$1.86
Analyst Ratings
The price target is $4.10 and the stock is covered by 6 analysts.
Buy
5
Hold
1
Sell
0
Information
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.
- Employees
- 91
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- MXCT
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet